CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2021
Income Statement [Abstract]
Net revenues	$ 140,866	$ 133,517	$ 278,413	$ 268,212	$ 535,031
Cost of revenues	28,503	28,599	56,230	54,984	114,877
Gross profit	112,363	104,918	222,183	213,228	420,154
Operating costs and expenses:
Research, development and clinical studies	57,075	50,315	99,309	96,231	201,303
Sales and marketing	44,750	34,138	82,634	65,495	137,057
General and administrative	31,666	32,760	62,174	63,885	126,127
Total operating costs and expenses	133,491	117,213	244,117	225,611	464,487
Operating income (loss)	(21,128)	(12,295)	(21,934)	(12,383)	(44,333)
Financial expenses (income), net	2,228	940	3,937	3,586	7,742
Income (loss) before income tax	(23,356)	(13,235)	(25,871)	(15,969)	(52,075)
Income tax	652	1,406	2,784	2,800	6,276
Net income (loss)	$ (24,008)	$ (14,641)	$ (28,655)	$ (18,769)	$ (58,351)
Basic net income (loss) per ordinary share (in usd per share)	$ (0.23)	$ (0.14)	$ (0.27)	$ (0.18)	$ (0.56)
Weighted average number of ordinary shares used in computing basic net income (loss) per share (in shares)	104,627,789	103,484,866	104,408,164	103,061,557	103,433,274
Diluted net income (loss) per ordinary share (in usd per share)	$ (0.23)	$ (0.14)	$ (0.27)	$ (0.18)	$ (0.56)
Weighted average number of ordinary shares used in computing diluted net income (loss) per share (in shares)	104,627,789	103,484,866	104,408,164	103,061,557	103,433,274